July 5, 2017 — Varian Medical Systems has received U.S. Food and Drug Administration (FDA) 510(k) clearance for the Halcyon system, its new device for cancer treatment. Halcyon simplifies and enhances virtually every aspect of image-guided volumetric intensity modulated radiotherapy (IMRT), according to the company.
Halcyon is an advanced system that is more comfortable for the patient while delivering ease of use for healthcare providers, accelerated installation timeframes, expedited commissioning, simplified training and automated treatment. With its streamlined workflow, the system only requires nine steps from the start to the end of treatment compared to up to more than 30 steps with older technologies. Halcyon is well suited to handle the majority of cancer patients, according to Varian, offering advanced treatments for prostate, breast, head & neck, and many other forms of cancer.
Halcyon features large touchscreens on both sides of the machine to assist in easy patient set-up. For increased patient comfort, Halcyon is up to two times quieter than other systems, has a low couch height for easy patient access and soft indirect ambient lighting in the gantry opening. To create a closer connection between patient and therapist during Halcyon treatment, the system includes an integrated couch-mounted camera for the therapist to watch over the patient during treatment, and an integrated noise-cancelling sound system that makes it easy for patients to converse with the therapists.
With 510(k) clearance, Varian can begin selling the Halcyon system in the United States. The system requires Eclipse 15.1.1 treatment planning software, which is currently 510(k) pending.
For more information: www.varian.com/halcyon
June 12, 2025 
